Guangzhou Bio-gene Technology Co., Ltd
21
10
10
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
14.3%
3 terminated/withdrawn out of 21 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Role: lead
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Role: lead
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
Role: collaborator
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
Role: lead
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Role: lead
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
Role: lead
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
Role: lead
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Role: lead
Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
Role: lead
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
Role: lead
Exosomes for Hairloss Treatment
Role: lead
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Role: lead
Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
Role: collaborator
Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
Role: lead
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
Role: collaborator
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
Role: collaborator
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Role: collaborator
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
Role: lead
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Role: collaborator
Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia
Role: lead